[go: up one dir, main page]

SI3555097T1 - Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz - Google Patents

Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz

Info

Publication number
SI3555097T1
SI3555097T1 SI201731186T SI201731186T SI3555097T1 SI 3555097 T1 SI3555097 T1 SI 3555097T1 SI 201731186 T SI201731186 T SI 201731186T SI 201731186 T SI201731186 T SI 201731186T SI 3555097 T1 SI3555097 T1 SI 3555097T1
Authority
SI
Slovenia
Prior art keywords
pyrrolo
imidazo
inhibitors
pyridine compounds
janus kinases
Prior art date
Application number
SI201731186T
Other languages
English (en)
Inventor
Tatiana Koudriakova
Kevin D. Kreutter
Kristi Leonard
Michele C. Rizzolio
Russell C. Smith
Mark S. Tichenor
Aihua Wang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SI3555097T1 publication Critical patent/SI3555097T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI201731186T 2016-12-16 2017-12-15 Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz SI3555097T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662435609P 2016-12-16 2016-12-16
US201762592680P 2017-11-30 2017-11-30
US201762596607P 2017-12-08 2017-12-08
EP17854175.1A EP3555097B1 (en) 2016-12-16 2017-12-15 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
PCT/US2017/066744 WO2018112379A1 (en) 2016-12-16 2017-12-15 Small molecule inhibitors of the jak family of kinases

Publications (1)

Publication Number Publication Date
SI3555097T1 true SI3555097T1 (sl) 2022-09-30

Family

ID=61692222

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731186T SI3555097T1 (sl) 2016-12-16 2017-12-15 Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz

Country Status (35)

Country Link
US (5) US10294226B2 (sl)
EP (2) EP4086256A1 (sl)
JP (2) JP7291077B2 (sl)
KR (1) KR102352462B1 (sl)
CN (1) CN110088105B (sl)
AU (3) AU2017377069B2 (sl)
CA (1) CA3046965A1 (sl)
CL (1) CL2019001626A1 (sl)
CO (1) CO2019006200A2 (sl)
CR (1) CR20190282A (sl)
DK (1) DK3555097T3 (sl)
EC (1) ECSP19042688A (sl)
ES (1) ES2922379T3 (sl)
HR (1) HRP20220885T1 (sl)
HU (1) HUE059274T2 (sl)
IL (1) IL267275B (sl)
JO (1) JOP20190143B1 (sl)
LT (1) LT3555097T (sl)
MD (1) MD3555097T2 (sl)
MX (2) MX2019007073A (sl)
MY (1) MY196260A (sl)
NI (1) NI201900060A (sl)
NZ (1) NZ755404A (sl)
PE (1) PE20191105A1 (sl)
PH (1) PH12019501254A1 (sl)
PL (1) PL3555097T3 (sl)
PT (1) PT3555097T (sl)
RS (1) RS63500B1 (sl)
SA (1) SA519402216B1 (sl)
SI (1) SI3555097T1 (sl)
SM (1) SMT202200326T1 (sl)
TW (1) TWI777997B (sl)
UA (1) UA125042C2 (sl)
WO (1) WO2018112379A1 (sl)
ZA (1) ZA201904615B (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125824C2 (uk) 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
HRP20220885T1 (hr) 2016-12-16 2022-12-09 Janssen Pharmaceutica Nv Spojevi imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaze
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
US10221173B2 (en) 2017-01-30 2019-03-05 Astrazeneca Ab Chemical compounds
WO2019241796A1 (en) 2018-06-15 2019-12-19 Reata Pharmaceuticals, Inc. Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma
TW202016110A (zh) * 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
US20200338051A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor
CA3142625A1 (en) 2019-06-06 2020-12-10 Highlightll Pharmaceutical (Hainan) Co., Ltd Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
CN110483514B (zh) * 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
US20230091250A1 (en) * 2020-02-21 2023-03-23 Zhuhai United Laboratories Co., Ltd. Crystalline form of jak inhibitor and application thereof
CN114149428B (zh) * 2020-09-08 2023-06-13 中国药科大学 吡啶并环类化合物及其制备方法、中间体、组合物和应用
WO2022189496A1 (en) 2021-03-11 2022-09-15 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
CN114432317A (zh) * 2021-05-31 2022-05-06 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物的用途
CN113861194B (zh) * 2021-11-10 2022-07-05 英维沃化工科技(广州)有限公司 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
EP1173435B1 (en) 1999-04-23 2003-07-30 SmithKline Beecham plc Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AR040233A1 (es) 2002-05-31 2005-03-23 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
ES2449197T5 (es) 2005-07-01 2022-04-28 Wyeth Llc Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3- quinolincarbonitrilo y procedimientos de preparación de las mismas
CA2615291A1 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
RU2015105591A (ru) 2008-06-10 2015-08-10 Эббви Инк. Новые трициклические соединения
DK2473510T3 (da) 2009-09-03 2014-10-20 Bristol Myers Squibb Co Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer
JP2011066747A (ja) * 2009-09-18 2011-03-31 Panasonic Corp 弾性波フィルタ
KR20120102724A (ko) 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
PL2506716T3 (pl) 2009-12-01 2017-10-31 Abbvie Inc Nowe związki tricykliczne
AR079984A1 (es) 2010-01-12 2012-03-07 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1
WO2011098673A1 (en) 2010-02-10 2011-08-18 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
EP2955181B1 (en) 2013-02-08 2019-10-30 Nissan Chemical Corporation Tricyclic pyrrolopyridine compound, and jak inhibitor
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
KR20170003521A (ko) 2014-05-14 2017-01-09 닛산 가가쿠 고교 가부시키 가이샤 3 고리성 화합물 및 jak 저해제
EP3303348B1 (en) 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
EP3371332A4 (en) 2015-11-04 2019-04-03 Mayo Foundation for Medical Education and Research METHOD AND MATERIALS FOR TREATING AUTOIMMUNE DISEASES
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
UA125824C2 (uk) 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
UA122035C2 (uk) 2016-12-16 2020-08-25 Пфайзер Інк. Агоністи рецептора glp-1 та їх застосування
US20190281874A1 (en) 2016-12-16 2019-09-19 Nestec S.A. Oligosaccharides for flavour generation
HRP20220885T1 (hr) 2016-12-16 2022-12-09 Janssen Pharmaceutica Nv Spojevi imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaze
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CN115109075B (zh) 2016-12-16 2024-09-20 伊莱利利公司 突变体idh1和idh2抑制剂
JP2020502117A (ja) 2016-12-16 2020-01-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺生物剤化合物
MX2019008331A (es) 2017-01-11 2020-01-14 Leo Pharma As Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
US10221173B2 (en) 2017-01-30 2019-03-05 Astrazeneca Ab Chemical compounds
EP3612030A4 (en) 2017-04-21 2021-04-28 Ikena Oncology, Inc. AHR INDOLE INHIBITORS AND THEIR USES
CN106881892B (zh) 2017-04-27 2020-10-16 双钱集团（江苏）轮胎有限公司 一种轮胎生产用生胎转移系统
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US20200338051A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Also Published As

Publication number Publication date
RS63500B1 (sr) 2022-09-30
AU2017377069B2 (en) 2020-07-23
JP2023071709A (ja) 2023-05-23
PL3555097T3 (pl) 2022-10-17
ES2922379T3 (es) 2022-09-14
US11059823B2 (en) 2021-07-13
CA3046965A1 (en) 2018-06-21
US20190177321A1 (en) 2019-06-13
PH12019501254A1 (en) 2020-01-20
NI201900060A (es) 2020-03-16
MX2019007073A (es) 2019-10-15
JP2020502113A (ja) 2020-01-23
PE20191105A1 (es) 2019-08-23
CN110088105B (zh) 2022-03-18
ECSP19042688A (es) 2019-06-30
EP3555097A1 (en) 2019-10-23
PT3555097T (pt) 2022-09-22
JOP20190143A1 (ar) 2019-06-13
CL2019001626A1 (es) 2019-10-04
JP7291077B2 (ja) 2023-06-14
AU2017377069A1 (en) 2019-06-20
US20190177322A1 (en) 2019-06-13
US10364246B2 (en) 2019-07-30
LT3555097T (lt) 2022-08-25
IL267275A (en) 2019-08-29
AU2020257068A1 (en) 2020-11-19
SA519402216B1 (ar) 2022-10-02
US20180170931A1 (en) 2018-06-21
US10294226B2 (en) 2019-05-21
US12202831B2 (en) 2025-01-21
TW201831180A (zh) 2018-09-01
NZ755404A (en) 2024-10-25
CR20190282A (es) 2019-08-21
BR112019011968A2 (pt) 2019-11-05
CO2019006200A2 (es) 2019-06-28
AU2022204240A1 (en) 2022-07-07
IL267275B (en) 2021-07-29
DK3555097T3 (da) 2022-07-25
HRP20220885T1 (hr) 2022-12-09
KR20190086779A (ko) 2019-07-23
US10487083B2 (en) 2019-11-26
KR102352462B1 (ko) 2022-01-17
MD3555097T2 (ro) 2022-12-31
EP4086256A1 (en) 2022-11-09
JP7493068B2 (ja) 2024-05-30
EP3555097B1 (en) 2022-06-15
UA125042C2 (uk) 2021-12-29
HUE059274T2 (hu) 2022-11-28
JOP20190143B1 (ar) 2023-09-17
ZA201904615B (en) 2021-05-26
US20190185474A1 (en) 2019-06-20
MY196260A (en) 2023-03-24
US20210340143A1 (en) 2021-11-04
WO2018112379A1 (en) 2018-06-21
TWI777997B (zh) 2022-09-21
SMT202200326T1 (it) 2022-09-14
AU2022204240B2 (en) 2023-10-05
MX2022004474A (es) 2023-08-15
CN110088105A (zh) 2019-08-02

Similar Documents

Publication Publication Date Title
SI3555097T1 (sl) Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
IL265918A (en) Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors
HK1258905A1 (zh) 作為ret激酶抑制劑的取代的吡唑並[1，5-a]吡啶化合物
HK1248675A1 (zh) 調節激酶的1h 吡咯並[2，3-b]吡啶衍生物的合成
HRP20171599T2 (hr) DERIVATI PIROLO[2,3-d]PIRIMIDINA KAO INHIBITORI JANUS KINAZA (JAK)
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
MX372939B (es) Inhibidores de cinasa janus 1 (jak1) para el tratamiento de sindromes mielodisplasicos.
PT3371185T (pt) Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
PL3712152T3 (pl) Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
SG11201606216UA (en) Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors